SCHEMBL6522334

SCHEMBL6522334

COCCC(=O)c1c(O)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.56
SERPINE1 P05121 1/20 0.53
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2A Q12879 1/20 0.49
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
GRIN3A Q8TCU5 1/20 0.49
KDM4E B2RXH2 1/20 0.47
CSF1R P07333 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516714 0.88 GSK3B (0.54) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6518138 0.87 GSK3B (0.56) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6519951 0.83 GSK3B (0.58) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6525473 0.82 MEN1 (0.58) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6507310 0.82 GSK3B (0.58) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6521717 0.81 GSK3B (0.49) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL6313673 0.81 GSK3B (0.56) GSK3BMEN1ALDH1A1MAPTKMT2A
SCHEMBL23510959 0.79 GRIN2D (0.58) GSK3BMEN1ALDH1A1MAPTKMT2A
SCHEMBL6515555 0.78 MEN1 (0.56) GSK3BSERPINE1MEN1ALDH1A1MAPT
SCHEMBL11383585 0.78 CSF1R (0.69) GSK3BALDH1A1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 GSK3B 824/4885SERPINE1 1022/4885MEN1 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.